CD274 and neoplasm: Interestingly, in a previous study, when we evaluated MS–OVA (enc) in combination with anti-PD-1, anti-CTLA-4 and anti-PD-L1 therapy, we were able to protect 70% of mice beyond 100 days after the tumor challenge [15], longer than obtained in the current study.